Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Modern Pathology

• Publication date

  2010-03-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/modpathol.2010.45PMID 20208477
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FGFR3 mutations in prostate cancer: association with low-grade tumors

  2009cited by this paper
• PTEN‐mediated pathways and their association with treatment‐resistant prostate cancer

  2009cited by this paper
• Mutations and Response to Epidermal Growth Factor Receptor Inhibitors

  2009cited by this paper
• Impact of EGFR mutation analysis in non-small cell lung cancer.

  2009cited by this paper
• Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

  2009cited by this paper
• Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer

  2008cited by this paper
• PI3K/PTEN signaling in tumorigenesis and angiogenesis.

  2008cited by this paper
• Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations

  2008cited by this paper
• PTEN mutation: many birds with one stone in tumorigenesis.

  2008cited by this paper
• Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma

  2008cited by this paper
• FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome

  2007cited by this paper
• Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer

  2007cited by this paper
• Epidermal growth factor receptor mutations in lung cancer

  2007cited by this paper
• The epidermal growth factor receptor: from development to tumorigenesis.

  2007cited by this paper
• Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

  2007cited by this paper
• Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

  2007cited by this paper
• PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.

  2007cited by this paper
• Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis

  2007cited by this paper
• Novel mutations of epidermal growth factor receptor in localized prostate cancer.

  2006cited by this paper
• The complexity of targeting EGFR signalling in cancer: from expression to turnover.

  2006cited by this paper
• Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer

  2006cited by this paper
• Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas

  2006cited by this paper
• Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array

  2006cited by this paper
• High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma.

  2006cited by this paper
• Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

  2006cited by this paper
• Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response

  2006cited by this paper
• Prevalent mutations in prostate cancer

  2006cited by this paper
• PTEN function in normal and neoplastic growth.

  2006cited by this paper
• Epidermal growth factor receptor (EGFR) signaling in cancer.

  2006cited by this paper
• Akt-regulated pathways in prostate cancer

  2005cited by this paper
• Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck

  2005cited by this paper
• Somatic Mutations of Epidermal Growth Factor Receptor in Colorectal Carcinoma

  2005cited by this paper
• Expression patterns of potential therapeutic targets in prostate cancer

  2005cited by this paper
• Human cancer, PTEN and the PI-3 kinase pathway.

  2004cited by this paper
• Racial disparity of epidermal growth factor receptor expression in prostate cancer.

  2004cited by this paper
• Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer.

  2003cited by this paper
• Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.

  2002cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression

  2001cited by this paper
• The multiple roles of PTEN in tumor suppression.

  2000cited by this paper
• Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

  1999cited by this paper
• Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems.

  1999cited by this paper
• PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate

  1998cited by this paper
• Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.

  1998cited by this paper
• Analysis of PTEN and the 10q23 region in primary prostate carcinomas

  1998cited by this paper
• PTEN/MMAC1/TEP1 involvement in primary prostate cancers

  1998cited by this paper
• Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.

  1997cited by this paper
• PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

  1997cited by this paper
• Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and malignant prostate tissue

  1994cited by this paper
• Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues.

  1993cited by this paper
• Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines.

  1990cited by this paper
• Membrane Potential of Brown Adipose Tissue

  1968cited by this paper

• Cellular signaling and radioresistance in prostate cancer.

  2026cites this paper
• Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERG

  2026cites this paper
• Novel Pyrido[2,3- d ]Pyrimidine Derivatives: Synthesis, In Silico and Cytotoxic Evaluation and Identification of a Potential Anticancer Agent

  2026cites this paper
• Molecular targeted therapies, omics, and AI based theranostics approaches for the treatment of prostate cancer.

  2025cites this paper
• Exploring Arylsulfatase B Role in Colorectal and Prostate Cancer Pathogenesis through AI-Driven Protein Interaction Prediction

  2025cites this paper
• Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer

  2025cites this paper
• Dicentrine and its N-oxide derivatives induces apoptotic and necrotic cell death in prostate cancer cell lines

  2025cites this paper
• Design, Synthesis, In Silico Evaluation, and Biological Assessment of Novel Pyrido[2,3‐d]Pyrimidine Derivatives as Potential Anticancer Agents

  2025cites this paper
• Gene Signature for Predicting Metastasis in Prostate Cancer Using Primary Tumor Expression Profiles

  2024cites this paper
• Development of 6-amido-4-aminoisoindolyn-1,3-diones as p70S6K1 inhibitors and potential breast cancer therapeutics

  2024cites this paper
• New approaches and prospects of immunotherapy and gene therapy for prostate cancer

  2024cites this paper
• Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?

  2023cites this paper
• Alpha Thalassemia/Intellectual Disability Syndrome X-Linked Expression Varies Significantly between Androgen Receptor-Positive and Androgen Receptor-Negative Prostatic Adenocarcinoma: Relation to Epidermal Growth Factor Receptor Expression and Clinicopathological Factors

  2023cites this paper
• Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients.

  2023cites this paper
• Synergistic Cytotoxicity of a Toxin Targeting the Epidermal Growth Factor Receptor and the Glycosylated Triterpenoid SO1861 in Prostate Cancer

  2023cites this paper
• Bioinspired thiazolo-[2,3-b] quinazolin-6-one derivatives as potent anti-cancer agents targeting EGFR: their biological evaluations and in silico assessment

  2023cites this paper
• The role of microRNAs in the development of radioresistance of prostate cancer cells (experimental study)

  2022cites this paper
• Loss of miR-936 leads to acquisition of androgen-independent metastatic phenotype in prostate cancer

  2022cites this paper
• Re-establishing the comprehension of phytomedicine and nanomedicine in inflammation-mediated cancer signaling.

  2022cites this paper
• Targeted Toxins for the Treatment of Prostate Cancer

  2021cites this paper
• AXL cooperates with EGFR to mediate neutrophil elastase-induced migration of prostate cancer cells

  2021cites this paper
• Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review

  2021cites this paper
• Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer

  2020cites this paper
• FAM46C inhibits cell proliferation and cell cycle progression and promotes apoptosis through PTEN/AKT signaling pathway and is associated with chemosensitivity in prostate cancer

  2020cites this paper
• Comparative expression of immunohistochemical biomarkers in cribriform and pattern 4 non-cribriform prostatic adenocarcinoma.

  2020cites this paper
• KRAS, BRAF, PIK3CA mutation frequency of radical prostatectomy samples and review of the literature

  2020cites this paper
• Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer.

  2020cites this paper
• An integrated genomic and metabolomic approach for defining survival time in adult oligodendrogliomas patients

  2019cites this paper
• The role of parenchyma-stroma relationships in carcinogenesis of the prostate gland (review)

  2019influential citation
• Rethink of EGFR in Cancer With Its Kinase Independent Function on Board

  2019cites this paper
• Identification of signalling pathways involved in the oxidative stress response triggered by Low Temperature Plasma in prostate epithelial cells and the assessment of tumour-associated allelic expression in prostate cancer

  2018cites this paper
• Investigating microRNA-7 as a potential therapeutic in cancer

  2018cites this paper
• Gleason 6 Tumors Should Still Be Labeled as Cancer

  2018cites this paper
• Paeonol enhances the sensitivity of human ovarian cancer cells to radiotherapy-induced apoptosis due to downregulation of the phosphatidylinositol-3-kinase/Akt/phosphatase and tensin homolog pathway and inhibition of vascular endothelial growth factor.

  2017cites this paper
• Clinical Utility and Biologic Implications of Phosphatase and Tensin Homolog (PTEN) and ETS-related Gene (ERG) in Prostate Cancer.

  2017cites this paper
• Recent advances of folate-targeted anticancer therapies and diagnostics: current status and future prospectives

  2017cites this paper
• The role of peroxisome proliferator-activated receptor gamma in prostate cancer

  2017cites this paper
• Prostate Cancer in African American Men: The Effect of Androgens and microRNAs on Epidermal Growth Factor Signaling

  2016cites this paper
• Signaling Pathways that Facilitate Chronic Inflammation-Induced Carcinogenesis

  2016cites this paper
• Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells “in vitro” and correlating with progression “in vivo”

  2016cites this paper
• PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for Active Surveillance

  2016cites this paper
• Association Study of Polymorphisms of Epidermal Growth Factor and Epidermal Growth Factor Receptor With Benign Prostatic Hyperplasia in a Korean Population

  2016cites this paper
• Advances in prostate cancer research models: From transgenic mice to tumor xenografting models

  2016cites this paper
• Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.

  2015cites this paper
• Should Gleason 6 be labeled as cancer?

  2015cites this paper
• UNC13B – A potential target gene of 9p13.3 amplicon in prostate cancer

  2015cites this paper
• Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.

  2015cites this paper
• The biology of castration-resistant prostate cancer.

  2015cites this paper
• Eupafolin suppresses prostate cancer by targeting phosphatidylinositol 3‐kinase‐mediated Akt signaling

  2015cites this paper
• Association of ERG and TMPRSS2‐ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels

  2015cites this paper
• Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy

  2014cites this paper
• ERG positive prostatic cancer may show a more angiogenetic phenotype.

  2014cites this paper
• Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition.

  2014cites this paper
• SGEF enhances EGFR stability through delayed EGFR trafficking from early to late endosomes.

  2013cites this paper
• Chapter 8 A Glance at the Complexity of Nutrition and the Prostate : Considering Molecular Targets to Unravel the Most Recent Controversy Between Omega-3 Fatty Acids and Their Impact on Prostate Cancer Risk

  2013cites this paper
• A Glance at the Complexity of Nutrition and the Prostate: Considering Molecular Targets to Unravel the Most Recent Controversy Between Omega-3 Fatty Acids and Their Impact on Prostate Cancer Risk

  2013cites this paper
• A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer

  2013cites this paper
• Disruption of Prostate Epithelial Differentiation Pathways and Prostate Cancer Development

  2013cites this paper
• Genomic Rearrangements of PTEN in Prostate Cancer

  2013cites this paper
• CLONING OF UBAP 2 AND ITS ROLE IN PROSTATE CANCER

  2013cites this paper
• Inhibition of EGFR signaling in prostate cancer treated with EGFR siRNA and Gefitinib Inhibition of EGFR signaling in prostate cancer treated with EGFR siRNA and Gefitinib.

  2012cites this paper
• The complexity of prostate cancer: genomic alterations and heterogeneity

  2012cites this paper
• Effect of PTEN Antisense Oligonucleotide on Oesophageal Squamous Cell Carcinoma Cell Lines

  2012cites this paper
• Biological significance of perineural invasion (PNI) in prostate cancer

  2012cites this paper
• Activating Mutations and Targeted Therapy in Cancer

  2012cites this paper
• PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications

  2012cites this paper
• CXCR4 mRNA overexpression in high grade prostate tumors: Lack of association with TMPRSS2-ERG rearrangement

  2012cites this paper
• Targeted Nanoparticles for Cancer Therapy

  2012cites this paper
• EGFR signaling pathway and related-miRNAs in age-related diseases: the example of miR-221 and miR-222

  2012cites this paper
• A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression.

  2012cites this paper
• Progress of molecular targeted therapies for prostate cancers.

  2012cites this paper
• Estudi dels gens FGFR3, EGFR, PTEN, CXCR4 i del gen de fusió TMPRSS2-ERG en càncer de pròstata

  2012cites this paper
• Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer

  2012cites this paper
• Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer

  2011cites this paper
• Unveiling the Molecular Mechanisms Regulating the Activation of the ErbB Family Receptors at Atomic Resolution through Molecular Modeling and Simulations

  2011cites this paper
• Diffuse Large B-Cell Lymphoma with Concurrent Gastric Adenocarcinoma: Case Report and Literature Review

  2011cites this paper
• Prostate cancer in Cowden syndrome: somatic loss and germline mutation of the PTEN gene.

  2011cites this paper
• Genomic predictors of prostate cancer therapy outcomes

  2010cites this paper
• Dietary Chemoprevention Studies in Preclinical Models of Prostate Cancer: Bioactive Lipids and Vitamin D

  2010cites this paper